Long-term Treatment Outcome for Stage III NPC Patients and Risk Grouping by Plasma EBV DNA

Long-term Treatment Outcome for Stage III Nasopharyngeal Carcinoma Patients and Risk Grouping by Plasma Epstein-Barr Virus DNA

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03314051

Enrollment

366

Registered

2017-10-19

Start date

2012-05-02

Completion date

2016-12-31

Last updated

2017-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

EBV Related Carcinoma, Nasopharyngeal Carcinoma

Keywords

Nasopharyngeal Carcinoma, plasma EBV DNA

Brief summary

No previous study reported the treatment outcome of stage III nasopharyngeal carcinoma (NPC) patients. The investigators try to investigate the long-term treatment outcome of stage III NPC patients and do risk grouping by plasma Epstein-Barr virus (EBV) DNA assay for future therapy improvement.

Detailed description

The stage III NPC patients were the majority group of the patient population of NPC. But most clinical trials focused on the treatment of American Joint Committee on Cancer (AJCC) 7th edition stage IVA/IVB treatment for high risk of recurrence or metastasis. No previous study reported the treatment outcome of stage III NPC patients. The investigators tried to investigate the long-term treatment outcome of stage III NPC patients and do risk grouping by plasma EBV DNA assay for future therapy improvement.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Biopsy-proven stage III nasopharyngeal carcinoma (NPC) * Finished curative chemoradiotherapy * Have Pre-treatment and post-radiotherapy plasma EBV DNA

Exclusion criteria

* No tissue proven NPC * Not finished curative treatment * No Pre-treatment and post- radiotherapy plasma EBV DNA

Design outcomes

Primary

Measure	Time frame	Description
Overall survival (OS)	5 year	Diagnosis to death

Secondary

Measure	Time frame	Description
Progression-free survival (PFS)	5 year	Diagnosis to death to recurrence or metastasis
Distant metastasis failure-free survival (DMFFS)	5 year	Diagnosis to death to distant metastasis
Locoregional failure-free survival (LRFFS)	5 year	Diagnosis to death to locoregional failure

Outcome results